Massive Bio
Still Running· since Aug 17, 2026
- 44
- days running
- 0
- relaunches
Ad copy
Newly diagnosed KRAS G12C-mutant NSCLC patients may be eligible for a first-line clinical trial. Support early referral.
🪄Crush AI
Like this ad? Make it yours.
Crush rebuilds this exact creative around your product — your brand, your colors, your offer — in about a minute.
